October 31, 2019 06:58 AM EDTUpdated 09:48 AM
R&D

Mer­ck­'s last crack at sal­vaging a $2.5B ju­ry ver­dict in hep C patent show­down is shot down by ap­peals court

Jason Mast

Editor

In De­cem­ber 2013, Gilead an­nounced the first pill that could cure he­pati­tis C. The same week, Idenix Phar­ma­ceu­ti­cals an­nounced it was su­ing Gilead for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times